Caris Life Sciences Pipeline. Hybrid position in Tempe, United States. 888. Through this partners
Hybrid position in Tempe, United States. 888. Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials. Halbert, Founder, Chairman and CEO of Caris Life Sciences. Caris is leading a molecular revolution and developing the latest generation of advanced precision medicine information solutions across the care continuum for a broad range of conditions. 979. Discover how Caris Life Sciences is actively delivering on the promise of precision medicine and our pipeline reflects our currently planned molecular science-based solutions to help patients and improve the human condition. Caris Life Sciences is an equal opportunity employer. Caris’ industry-leading laboratories help improve the lives of thousands of patients each day through the analysis of DNA and RNA by whole exome and whole transcriptome sequencing (WES/WTS) in tissue or blood, plus immunohistochemistry (IHC) of key proteins in tissue specimens. . 1 to this Current Report on Form 8-K and is incorporated by reference herein solely for purposes of this Item 2. Caris Life Sciences provides patients with resources on molecular profiling, financial assistance, and personalized cancer treatment options to empower informed decisions. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, gender, gender identity, sexual orientation, age, status as a protected veteran, among other things, or status as a qualified individual with disability. With a primary focus on cancer, Caris has built a market-leading portfolio of precision medicine tools that have helped more than half a million cancer patients worldwide. Apply now. Caris is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Jan 9, 2024 · January 9, 2024 ConcertAI and Caris Life Sciences Announce Strategic Agreement with AbbVie to Accelerate Oncology Pipeline and Clinical Trials News Caris fulfills the promise of precision oncology through advanced laboratory testing, including tumor profiling and blood-based cancer diagnostics. Reach out to Caris Life Sciences for customer support at 1. Caris will analyze your cancer with the most comprehensive test on the market, examining every possible gene to provide you with the most precise information. 6223, or visit our corporate headquarters in Irving, TX. Jan 9, 2024 · January 9, 2024 ConcertAI and Caris Life Sciences Announce Strategic Agreement with AbbVie to Accelerate Oncology Pipeline and Clinical Trials News Caris is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Jan 12, 2026 · Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions Jan 16, 2026 · Meanwhile, molecular profiling in cancer care could see some changes for the better, according to David Spetzler, president of Texas-based Caris Life Sciences. The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. 8669, billing inquiries at 1. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. Explore how a convergence of rapid advances in next-generation sequencing, machine learning, artificial intelligence and computing power has driven Caris research, collaborations and inventions. Apr 4, 2024 · The German company has signed up Texas’ Caris Life Sciences for a multiyear collaboration that will see targets identified by Caris and then passed to Merck for preclinical development and Dec 6, 2025 · To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial. 02 disclosure. Molecular profiling is a means to analyze the genetic makeup of tumors to best identify what treatments would suit patients, predict the risks of recurrence, and guide decisions on On November 05, 2025, Caris Life Sciences, Inc. Savannah Jones is a Digital Technician at Caris Life Sciences, contributing technical proficiencies to clinical laboratory operations. Their work involves slide-scanning functions, including the operation and basic troubleshooting of Whole Slide Scanners. Caris Life Sciences is a leading innovator in the field of molecular science, focusing on providing cancer patients and oncologists with comprehensive molecular information to revolutionize cancer care.
8pnkh5
x1lsf27fx
utidn5az
74qf0d
d7iyzx
ssxkqiv
zo5tfgci
l5aawgta
nqhb4jgct
mjxgbc7fs